NICE Recommends Astellas Pharma’s Xospata for Acute Myeloid Leukemia

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Astellas Pharma’s Xospata (gilteritinib) for treatment of adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not improved after previous treatment.

NICE said the drug meets its criteria for a life-extending treatment, but it noted uncertainty about the long-term survival of treated patients following a stem cell transplant.

Astellas has agreed to make Xospata available to the UK’s National Health Service at a discounted price.